Buy Aurobindo Pharma; target of Rs 1300: ICICI Securities

ICICI Securities is bullish on Aurobindo Pharma has recommended buy rating on the stock with a target price of Rs 1300 in its research report dated August 06, 2025.

Broker Research

August 07, 2025 / 13:14 IST

BUY

26 Aug, 2025 12:21

Volume

Todays L/H

ICICI Securities's research report on Aurobindo Pharma

Aurobindo’s Q1FY26 result was dragged by lower revenue of gRevlimid (impact of 2% YoY/~7% QoQ) and API (-16% YoY). Gross / EBITDA margins at 58.8%/20.4% were impacted by lower gRevlimid and PLI income and Pen-g plant cost (INR 500mn). While gRevlimid’s revenue for next two quarters may be soft, management has maintained its EBITDA margin guidance of 20-21% for FY26 (20.8% in FY26). Manufacturing at Pen-G plant resumed in Jul’25 and a pick-up is likely in Q3FY26. Acquisition of Lannett could complete in nine months and may add 6-7% to revenue and ~2% to EPS (not factored in our estimates) in FY27E. Timeline for other growth projects like biosimilars and biologic CDMO is intact for H2FY26. Cut FY26E EPS by ~7% to factor in lower gRevlimid sales and other income. Upgrade to BUY but trim TP to INR 1,300, based on 16x FY27E EPS.

Outlook

We cut FY26E EPS by ~7% to factor in lower gRevlimid revenue and other income and maintain our FY27 estimates. The stock currently trades at 16.7x FY26E and 13.1x FY27E earnings, and EV/EBITDA multiples of 8.4x FY26E and 6.8x FY27E. We upgrade to BUY (earlier Add) but lower target price to INR 1,300 (INR 1,330 earlier), based on 16x FY27E EPS (unchanged).

For all recommendations report, click here